Helen Louise Collins - Apr 4, 2023 Form 4 Insider Report for Enliven Therapeutics, Inc. (ELVN)

Role
Chief Medical Officer
Signature
/s/ Ben Hohl, by power of attorney
Stock symbol
ELVN
Transactions as of
Apr 4, 2023
Transactions value $
$0
Form type
4
Date filed
4/6/2023, 08:32 PM
Previous filing
Feb 27, 2023
Next filing
Jun 2, 2023

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ELVN Stock Option (right to buy) Award $0 +206K $0.00 206K Apr 4, 2023 Common Stock 206K $22.75 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 1/4th of the shares subject to the option will vest on February 23, 2024 and 1/48th of the shares subject to the option will vest each month thereafter, subject to the Reporting Person continuing as a service provider through each such date